US limits Covid boosters to over-65s or those at high risk

Listen to article

WASHINGTON:

The United States will limit Covid-19 boosters to people over 65 or those at risk of serious illness, while requiring vaccine makers to run fresh clinical trials before offering shots to younger and healthier individuals, officials said Tuesday.

Writing in the New England Journal of Medicine, the Food and Drug Administration's Vinayak Prasad and Commissioner Martin Makary framed the policy shift as "evidence-based" and would align the United States more closely with guidance in Europe.

But it comes as Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, pushes to remake federal public health policy.

Kennedy previously led a nonprofit that was critical of immunization programs, and during the pandemic petitioned the FDA to revoke Covid vaccine authorizations, citing rare side effects including heart inflammation.

Prasad and Makary praised the initial Covid-19 vaccine rollout as "a major scientific, medical, and regulatory accomplishment," but argued that the benefits of repeated boosters for low-risk individuals are uncertain.

They criticized the US approach of recommending boosters for all adults regardless of age or health status, calling it a "one-size-fits-all" model based on the mistaken belief that Americans couldn't handle more nuanced, risk-based advice.

Rather than building public trust, they wrote, it had backfired — fueling vaccine hesitancy that has spilled over into skepticism toward childhood shots, including those for measles.

The FDA said it would rely on lab test results to approve boosters for people who are over 65, or over six months old with at least one underlying condition.

But for healthy individuals between six months and 64 years, regulators will now require data from randomized trials.

"We simply don't know whether a healthy 52-year-old woman with a normal BMI (body mass index) who has had Covid-19 three times and has received six previous doses of a Covid-19 vaccine will benefit from the seventh dose," they wrote.

Some infectious disease experts welcomed the shift.

Amesh Adalja of Johns Hopkins University said it matched with the approach taken by other countries in a population that already carries significant immunity.

"For lower-risk individuals, the goal has always been less clear, as protection against infection is transient and they don't have a high risk of severe disease," he told AFP.

But others voiced concern about the practical consequences. Paul Offit, a leading vaccine expert at the Children's Hospital of Philadelphia, said it could limit access for people who still want boosters.

"Any use, say in a healthy 35-year-old, would be considered off-label, and you wonder whether an insurance company would pay for it," he told AFP.

Under the revised framework, companies like Pfizer and Moderna will be encouraged to test updated boosters in adults aged 50 to 64.

These studies should measure whether the vaccines reduce symptomatic infections, hospitalizations and deaths.

Rather than comparing new shots to earlier formulations, Prasad and Makary suggested placebo-controlled trials -- with saline as the comparator -- to better evaluate both benefit and potential side effects.

The proposal, first floated by Kennedy earlier this month, has proved divisive. Critics argue that using a placebo -- when authorized vaccines already exist -- could expose participants to unnecessary harm.

"Imagine if there was a death or two in the placebo group," said Offit. "I don't see how you conscience that."

Supporters of continued Covid-19 boosters often draw parallels to annual flu shots. AFp